Renal Effects of Levosimendan: A Consensus Report

• Type: Another Publication in an International Scientific Journal
• Date: 2013

Authors

Yilmaz, MB (Author) Other; Grossini, E (Author) Other; Silva Cardoso, J (Author) FMUP; Edes, I (Author) Other; Fedele, F (Author) Other; Pollesello, P (Author) Other; Kivikko, M (Author) Other; Harjola, VP (Author) Other; Hasslacher, J (Author) Other; Mebazaa, A (Author) Other; Morelli, A (Author) Other; le Noble, J (Author) Other; Oldner, A (Author) Other; Oulego Erroz, IO (Author) Other; Parissis, JT (Author) Other; Parkhomenko, A (Author) Other; Poelzl, G (Author) Other; Rehberg, S (Author) Other; Ricksten, SE (Author) Other; Rodriguez Fernandez, LMR (Author) Other; Salmenpera, M (Author) Other; Singer, M (Author) Other; Treskatsch, S (Author) Other; Vrtovec, B (Author) Other; Wikstrom, G (Author) Other

Journal

Title: Cardiovascular Drugs and Therapy

Vol. 27

Pages: 581-590

ISSN: 0920-3206

Publisher: Springer Nature

Indexing

ISI Web of Knowledge - 46 Citations

Scopus - 54 Citations

Other information

Authenticus ID: P-008-PWV

DOI: 10.1007/s10557-013-6485-6

Abstract (EN): Renal dysfunction is common in clinical settings in which cardiac function is compromised such as heart failure, cardiac surgery or sepsis, and is associated with high morbidity and mortality. Levosimendan is a calcium sensitizer and potassium channel opener used in the treatment of acute heart failure. This review describes the effects of the inodilator levosimendan on renal function. A panel of 25 scientists and clinicians from 15 European countries (Austria, Finland, France, Hungary, Germany, Greece, Italy, Portugal, the Netherlands, Slovenia, Spain, Sweden, Turkey, the United Kingdom, and Ukraine) convened and reached a consensus on the current interpretation of the renal effects of levosimendan described both in non-clinical research and in clinical study reports. Most reports on the effect of levosimendan indicate an improvement of renal function in heart failure, sepsis and cardiac surgery settings. However, caution should be applied as study designs differed from randomized, controlled studies to uncontrolled ones. Importantly, in the largest HF study (REVIVE I and II) no significant changes in the renal function were detected. As it regards the mechanism of action, the opening of mitochondrial K-ATP channels by levosimendan is involved through a preconditioning effect. There is a strong rationale for randomized controlled trials seeking beneficial renal effects of levosimendan. As an example, a study is shortly to commence to assess the role of levosimendan for the prevention of acute organ dysfunction in sepsis (LeoPARDS).

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 10